Loading...
•
Jun 30, 2024
Evofem Biosciences Q2 2024 Earnings Report
Evofem Biosciences reported improved operating loss by 81% and acquired SOLOSEC in Q2 2024.
Key Takeaways
Evofem Biosciences announced its Q2 2024 financial results, featuring a net product sales increase to $4.2 million compared to $2.5 million in the prior year period. The company also reported an improved operating loss of $1.4 million compared to $7.3 million in the same period last year. They acquired SOLOSEC and forged a commercial agreement for Phexxi in the Middle East.
Net product sales were $4.2 million, up from $2.5 million in the prior year period.
Operating loss improved to $1.4 million, compared to $7.3 million in the prior year period.
Net income attributable to common stockholders was $1.3 million, or $0.02 per share.
Acquired SOLOSEC, a single-dose oral antibiotic, and forged an ex-U.S. commercial agreement for Phexxi in the Middle East.
Evofem Biosciences
Evofem Biosciences
Forward Guidance
The press release includes forward-looking statements regarding anticipated financial performance, the relaunch of SOLOSEC, and the closing of the Aditxt transaction. Actual results may differ due to risks and uncertainties detailed in the company's SEC filings.